

SKIN

A protective Langerhans cell–keratinocyte axis that is dysfunctional in photosensitivity

William D. Shipman^{1,2,3}, Susan Chyou³, Anusha Ramanathan³, Peter M. Izmirlly⁴, Sneha Sharma^{5,6}, Tania Pannellini³, Dragos C. Dasoveanu^{3,7}, Xiaoping Qing³, Cynthia M. Magro⁸, Richard D. Granstein⁹, Michelle A. Lowes¹⁰, Eric G. Pamer⁶, Daniel H. Kaplan^{11,12}, Jane E. Salmon^{2,3,13,14}, Babak J. Mehrara¹⁵, James W. Young^{5,6,10,13,16}, Robert M. Clancy⁴, Carl P. Blobel^{7,13,17,18}, Theresa T. Lu^{2,3,14,19*}

Copyright © 2018
The Authors, some
rights reserved;
exclusive licensee
American Association
for the Advancement
of Science. No claim
to original U.S.
Government Works

Photosensitivity, or skin sensitivity to ultraviolet radiation (UVR), is a feature of lupus erythematosus and other autoimmune and dermatologic conditions, but the mechanistic underpinnings are poorly understood. We identify a Langerhans cell (LC)–keratinocyte axis that limits UVR-induced keratinocyte apoptosis and skin injury via keratinocyte epidermal growth factor receptor (EGFR) stimulation. We show that the absence of LCs in Langerin–diphtheria toxin subunit A (DTA) mice leads to photosensitivity and that, *in vitro*, mouse and human LCs can directly protect keratinocytes from UVR-induced apoptosis. LCs express EGFR ligands and a disintegrin and metalloprotease 17 (ADAM17), the metalloprotease that activates EGFR ligands. Deletion of ADAM17 from LCs leads to photosensitivity, and UVR induces LC ADAM17 activation and generation of soluble active EGFR ligands, suggesting that LCs protect by providing activated EGFR ligands to keratinocytes. Photosensitive systemic lupus erythematosus (SLE) models and human SLE skin show reduced epidermal EGFR phosphorylation and LC defects, and a topical EGFR ligand reduces photosensitivity. Together, our data establish a direct tissue-protective function for LCs, reveal a mechanistic basis for photosensitivity, and suggest EGFR stimulation as a treatment for photosensitivity in lupus erythematosus and potentially other autoimmune and dermatologic conditions.

INTRODUCTION

Photosensitivity, a sensitivity to ultraviolet radiation (UVR) whereby even ambient sunlight exposure can result in inflammatory skin lesions, is a common feature in cutaneous and systemic forms of lupus erythematosus and can also occur with other autoimmune conditions, a number of dermatologic conditions, and as a response to drugs such as fluoroquinolone antibiotics (1–3). The photosensitive lesions can be disfiguring and, in systemic lupus erythematosus (SLE), can be associated with systemic disease flares (1, 2). The pathogenesis of photosensitivity is poorly understood, and treatments consist mainly of sun avoidance and sunscreen to prevent lesion development (2). A better understanding of the mechanistic basis of photosensitivity could lead to improved disease treatment.

Keratinocyte apoptosis occurs rapidly after UVR exposure, and photosensitivity is associated with increased keratinocyte apoptosis (4, 5). In autoimmune diseases, apoptotic keratinocytes can display autoantigens that bind autoantibodies, leading to complement activation and sustained skin inflammation (1, 5). The localization of “sunburn cells,” or apoptotic keratinocytes, with lupus erythematosus skin lesions (6) further supports the idea that keratinocyte apoptosis is part of the pathophysiology. Keratinocytes are critical for normal skin barrier function (7), and even in the absence of autoimmunity, increased keratinocyte death and failure to compensate have the potential to lead to skin injury and inflammation (8). However, mechanisms that limit UVR-induced keratinocyte apoptosis that are dysfunctional in photosensitivity are not well understood.

In addition to keratinocytes, the epidermis contains a population of well-described Langerin⁺ dendritic antigen-presenting cells, known as Langerhans cells (LCs). LCs are primarily associated with their antigen presentation functions: capturing antigens in the epidermis, migrating from the skin to the draining lymph node, and initiating T cell responses (9, 10). In lupus skin lesions, LCs have an abnormal morphology and are reduced in number (11), suggesting the possibility of a regulatory role. However, in the MRL-*Fas*^{pr} SLE mouse model, the role of LCs in spontaneous (that is, non-UVR-induced) skin lesion development has been examined with mixed conclusions; constitutive LC absence had no effect on skin lesions (12), whereas acute depletion of LCs and Langerin⁺ dermal dendritic cells (DCs) increased lesions, and this was attributed to loss of T cell tolerance (13). Thus, the role of LCs in photosensitivity and as a potential direct modulator of keratinocyte function has not been explored.

We and others have recently shown that DCs can directly modulate stromal elements in lymph nodes, adipose tissues, and skin (14–18). Because LCs have DC characteristics (9, 10), we asked whether LCs modulated keratinocyte survival and skin injury after UVR exposure.

¹Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program, New York, NY 10065, USA. ²Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, USA. ³Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY 10021, USA. ⁴Department of Medicine, New York University School of Medicine, New York, NY 10016, USA. ⁵Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. ⁶Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. ⁷Department of Physiology, Biophysics and Systems Biology, Weill Cornell Medicine, New York, NY 10065, USA. ⁸Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA. ⁹Department of Dermatology, Weill Cornell Medicine, New York, NY 10065, USA. ¹⁰Rockefeller University, New York, NY 10065, USA. ¹¹Department of Dermatology, University of Pittsburgh, PA 15260, USA. ¹²Department of Immunology, University of Pittsburgh, PA 15260, USA. ¹³Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA. ¹⁴Division of Rheumatology and Pediatric Rheumatology, Hospital for Special Surgery, New York, NY 10021, USA. ¹⁵Division of Plastic and Reconstructive Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. ¹⁶Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. ¹⁷Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, NY 10021, USA. ¹⁸Institute for Advanced Studies, Technical University Munich, Munich, Germany. ¹⁹Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY 10065, USA.

*Corresponding author. Email: lut@hss.edu

Here, we delineate an LC-keratinocyte axis whereby LCs limit UVR-induced keratinocyte apoptosis and skin injury by activating epidermal growth factor receptor (EGFR). This axis is dysfunctional in photosensitive SLE mouse models, and there is also evidence of dysfunction in human SLE. Photosensitivity in one of the SLE models is reduced by EGFR ligand supplementation. Together, our results identify a tissue-protective function for LCs, provide insight into mechanisms that limit skin injury, and suggest that EGFR stimulation may be an approach for treatment of photosensitivity in lupus erythematosus and other diseases.

RESULTS

LCs limit UVR-induced keratinocyte apoptosis and skin injury

LCs are positioned within the epidermis with keratinocytes (fig. S1, A and B), suggesting that LCs have the potential to modulate UVR-induced keratinocyte apoptosis. To test this idea, we used the Langerin-diphtheria toxin subunit A (DTA) mouse model that is constitutively depleted of LCs (fig. S1C) but not of Langerin⁺ dermal DCs (19). We treated wild-type (WT) and Langerin-DTA mice with UVR and examined the skin at 24 hours (Fig. 1A). In WT mice, epidermal LCs were reduced by half with UVR (fig. S1C), likely due to LC emigration (9, 10). As expected, UVR induced an increase in activated caspase-3⁺ cells in the epidermis (Fig. 1B, left). These cells were Langerin⁻ (fig. S1D) and CD3⁻ (fig. S1E), consistent with the idea that the apoptotic cells were keratinocytes. The lack of activated caspase-3⁺ Langerin⁺ cells also suggested that LCs were not ingesting apoptotic keratinocytes. Langerin-DTA mice showed increased numbers of activated caspase-3⁺ keratinocytes relative to WT mice (Fig. 1B, right), and this occurred as early as 3 hours after UVR exposure (fig. S1F). Langerin-DTA mice had greater monocyte accumulation (Fig. 1C). This was associated with greater numbers of monocyte-derived DCs (fig. S1G), whereas CD11b⁻ DCs, CD11b⁺ DCs, macrophages, and neutrophils did not increase in Langerin-DTA mice (fig. S1G). Our UVR source provided both ultraviolet A and B radiation (20), and increased UVR-induced keratinocyte apoptosis and monocyte accumulation in Langerin-DTA




Fig. 1. LCs limit UVR-induced keratinocyte apoptosis and skin injury. (A to H) WT and Langerin-DTA mice were exposed to UVR and examined. (A) Experimental scheme for (B) and (C); ears were harvested 24 hours after UVR. (B) Activated (Activ.) caspase-3⁺ keratinocytes per high-powered field (HPF). Left: Representative images of Langerin (red) and activated caspase-3 (green) stain. Right: Quantification ($n = 3$ to 9 mice). Scale bars, 50 μm . (C) Absolute (left) and normalized (right) monocyte numbers assessed by flow cytometry ($n = 3$ to 7 mice). (D) Experimental scheme for (E) and (F); ears were harvested 5 days (d5) after UVR. (E) Epidermal thickness ($n = 3$ to 7 mice). (F) Epidermal permeability as assessed by toluidine blue penetrance. Left: Representative images. Right: Quantification ($n = 3$ to 5 mice). (G) Experimental scheme for (H); mice were exposed to UVR for 3 days and examined 24 hours later. (H) Left: Representative images of back skin. Right: Lesional area quantification ($n = 3$ to 5 mice). Bars represent means (B, C, F, and H) or medians (E). Error bars depict SDs (B, C, F, and H) or interquartile ranges (E). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ using two-tailed unpaired Student's t test (B, C, F, and H) or nonparametric nondirectional Mann-Whitney U test (E) after one-way analysis of variance (ANOVA). Data are from nine (B), five (C), four (E), two (F), and three (H) independent experiments.

mice remained when UVB was blocked by use of a Mylar filter (fig. S1, H to J), suggesting that LCs limit the effects of, at least, UVA. Together, these results suggested that LCs limit UVR-induced keratinocyte apoptosis and skin inflammation.

We assessed additional parameters of skin function. UVR exposure induces epidermal hyperplasia within several days (21), and Langerin-DTA mice showed less epidermal thickening than WT mice (Fig. 1, D and E). Epidermal barrier function is compromised despite the hyperplasia (22), and Langerin-DTA skin showed greater tissue penetration of toluidine blue (23) than WT skin (Fig. 1F), suggesting worsened barrier function. Consistent with worsened skin function, Langerin-DTA mice showed a greater lesional area after exposure to multiple UVR doses (Fig. 1, G and H, and fig. S1K). These results together suggested that LCs limit the extent of UVR-induced skin injury.

We next attempted to assess whether the monocytes that accumulated in UVR-treated skin contributed to the UVR-induced damage. Consistent with the work of Tamoutounour *et al.* (24), we identified CCR2⁺ monocytes and monocyte-derived DCs in inflamed skin, and CD11b⁺ DCs were also CCR2⁺ (fig. S2A). Monocytes and monocyte-derived DCs comprised the vast majority of CCR2⁺ cells (fig. S2B). LCs were CCR2⁻ (fig. S2C). We depleted the CCR2⁺ cells using CCR2-DTR mice (fig. S2D) (25). The depletion did not alter UVR-induced keratinocyte apoptosis or epidermal thickness (fig. S2, E and F) but reduced toluidine blue penetration (fig. S2G). Although we cannot rule out a role for the CD11b⁺ DCs, these data raise the possibility that an increased number of infiltrating monocytes and monocyte-derived cells contributed to the worsened barrier function in Langerin-DTA mice.

LCs directly protect keratinocytes

T cells also inhabit the epidermis (Fig. 2A) (9), and we asked whether LCs limited UVR-induced skin injury via T cells. Rag1^{-/-} Langerin-DTA

mice lacking both lymphocytes and LCs showed higher UVR-induced keratinocyte apoptosis than Rag1^{-/-} mice (Fig. 2B). Although Rag1^{-/-} mice showed higher UVR-induced monocyte accumulation than WT mice (Fig. 2C), Rag1^{-/-} Langerin-DTA mice showed even greater monocyte accumulation (Fig. 2C). These results suggested that LC-mediated skin protection was independent of antigen presentation to T cells and that LCs could potentially limit keratinocyte apoptosis directly.

We tested for direct LC-keratinocyte interactions using LC-keratinocyte cocultures. UVR induces keratinocyte apoptosis *in vitro* (26), and addition of LCs reduced the apoptosis (Fig. 2, D and E). Essentially, no activated caspase-3⁺ cells were Langerin⁺ (fig. S3A), suggesting that the LC-mediated reduction in apoptotic keratinocytes was not due to apoptotic keratinocyte ingestion and clearance. These effects were not due to phototoxicity from the phenol red-containing culture medium because results were similar in phenol red-free medium (fig. S3B). Together, these results suggested that LCs limit UVR-induced keratinocyte apoptosis and skin injury *in vivo* by direct interactions with keratinocytes.

LCs limit UVR-induced keratinocyte apoptosis and skin injury by stimulating epidermal EGFR

Because keratinocyte EGFR signaling protects against UVR-induced keratinocyte apoptosis (21, 27) and contributes to maintaining epidermal barrier function and limiting skin inflammation (7, 28), we hypothesized that the LC-mediated skin protection involved EGFR signaling. Treatment of WT mice with PD168393, an irreversible EGFR inhibitor (29), reduced epidermal EGFR phosphorylation at tyrosine 1068 (fig. S4, A and B), a residue associated with keratinocyte survival after UVR (27). Ninety-eight percent of epidermal EGFR⁺ cells was keratinocytes (fig. S4, C and D), suggesting that the epidermal EGFR phosphorylation in Western blots reflected mainly keratinocyte




Fig. 2. LCs limit UVR-induced keratinocyte apoptosis directly. (A) Whole-mount stain of homeostatic mouse epidermis for CD3 (red), Langerin (green), and 4',6-diamidino-2-phenylindole (DAPI; blue). (B and C) Rag1^{-/-}, Rag1^{-/-} Langerin-DTA, WT, and Langerin-DTA mice were exposed to UVR, and ears were harvested 24 hours later ($n = 3$ to 8 mice). (B) Activated caspase-3⁺ keratinocytes. n.s., not significant. (C) Absolute (left) and normalized (right) monocyte numbers. (D and E) Effect of LCs on keratinocyte survival *in vitro*. Murine keratinocyte cultures without and with LCs were exposed to UVR and examined 24 hours later ($n = 3$ mice). (D) Representative images of keratinocytes stained for Langerin (green), activated caspase-3 (red), and DAPI (blue). (E) Activated caspase-3⁺ keratinocytes. (E) Data are from five (B and C) and three (A, D, and E) independent experiments. Scale bars, 50 μm . (B, C, and E) Bars represent means. Error bars depict SDs. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ using two-tailed unpaired Student's *t* test after one-way ANOVA.

signaling. EGFR inhibition led to increased UVR-induced keratinocyte apoptosis and skin injury (fig. S4, E to H), resembling results from Langerin-DTA mice and supporting the idea that LCs may limit UVR-induced skin injury by modulating keratinocyte EGFR signaling.


We then examined the effects of LC absence on UVR-induced keratinocyte epidermal EGFR activation. EGFR showed increased phosphorylation by 1 hour after UVR exposure (fig. S4I) (21), so we assessed this time point in subsequent experiments. The epidermis from Langerin-DTA mice had a modest reduction in homeostatic EGFR phosphorylation (Fig. 3A), and phosphorylation was not up-regulated after UVR (Fig. 3B). These results suggested that LCs mediated the UVR-induced keratinocyte EGFR activation.

We asked whether the LC-dependent EGFR stimulation was protective for keratinocytes. Treatment of Langerin-DTA mice with heparin-binding EGF-like growth factor (HB-EGF), a potent EGFR ligand (30), reduced UVR-induced apoptotic keratinocyte and monocyte accumulation (Fig. 3, C and D). In vitro, adding human LCs or HB-EGF to keratinocytes was similar in limiting UVR-induced apoptosis (Fig. 3E and fig. S5A). Furthermore, small interfering RNA (siRNA)-mediated knockdown of *Egfr* (fig. S5B) or EGFR inhibition in keratinocytes (fig. S5C) abolished the protective effect of LCs (Fig. 3, F and G), whereas EGFR inhibition in LCs did not (fig. S5, D and E). Together, these results suggested that LCs limit UVR-induced keratinocyte apoptosis and skin inflammation by stimulating keratinocyte EGFR.

LC ADAM17 is critical for limiting photosensitivity and is activated by UVR

We asked whether LCs could be a key source of EGFR ligands. Both murine and human LCs expressed multiple EGFR ligands, such as epigen and amphiregulin, which were up-regulated by UVR exposure in murine LCs (Fig. 4, A and B). A disintegrin and metalloprotease 17 (ADAM17) is a membrane-associated metalloprotease that is necessary for the cleavage and activation in cis of all EGFR ligands except EGF and β -cellulin (31), the two ligands not expressed or minimally expressed by LCs (Fig. 4, A and B). Murine and human LCs expressed ADAM17 (fig. S6, A to C). The expression of both EGFR ligands and ADAM17 supported the idea that LCs were potentially capable of directly activating keratinocyte EGFR.

Because LCs expressed multiple EGFR ligands, we assessed the role of LC-derived EGFR ligands by crossing ADAM17^{flox/flox} mice (32) with Langerin-Cre^{+/-} mice (33) to generate Langerin-Cre^{+/-}ADAM17^{flox/flox} mice (LC-Ad17 mice) that have *Adam17* constitutively deleted from LCs (fig. S6D). The Langerin-Cre driver itself had no effect on UVR-induced keratinocyte apoptosis (fig. S6E), so experiments henceforth used Langerin-Cre^{-/-}ADAM17^{flox/flox} mice as controls (WT). Although WT and LC-Ad17 mice had comparable






Fig. 4. LCs express EGFR ligands, and LC-derived ADAM17 mediates UVR-induced epidermal EGFR phosphorylation. (A and B) Murine (A) and human (B) LC EGFR ligand expression ($n = 3$ to 4 mice or human donors). Murine LCs were sorted from control or UVR-exposed mice. Expression of each ligand was normalized to control murine *Epgn* or human *Epgn* expression. n.d., not detectable. (C and D) WT and LC-Ad17 mice were treated with UVR and analyzed at indicated time points. (C) LC numbers ($n = 3$ to 5 mice). (D) Epidermal EGFR phosphorylation. Left: Representative Western blot. Right: pEGFR/EGFR ratio. Dashed lines are the values for the UVR-exposed WT (blue) and Langerin-DTA (red) mice shown in the blot. Uncropped Western blots are shown in fig. S13. Data are from three (A and B), four (C), and two (D) independent experiments. Bars represent means. Error bars depict SDs. * $P < 0.05$, ** $P < 0.01$ using two-tailed unpaired Student's *t* test. Student's *t* test was performed after one-way ANOVA for (C) and (D).

LC numbers (Fig. 4C), LC-Ad17 mice showed reduced UVR-induced epidermal EGFR phosphorylation (Fig. 4D), suggesting that LC-derived ADAM17 was important for UVR-induced keratinocyte EGFR activation.

We further asked about the importance of LC ADAM17 in protecting the skin. The LC-Ad17 mice showed increased accumulation of apoptotic keratinocytes, monocytes, and monocyte-derived DCs (Fig. 5, A and B, and fig. S6, F and G), blunted epidermal hyperplasia (Fig. 5C), and increased epidermal permeability (Fig. 5D) after UVR exposure. Inducible deletion in LCs (34) of ADAM17 in Langerin-Cre-ER^{+/-} ADAM17^{lox/lox} mice also increased UVR-induced keratinocyte apoptosis and monocyte accumulation (fig. S7, A to E). HB-EGF treatment dampened the increased UVR-induced keratinocyte apoptosis and skin inflammation in LC-Ad17 mice (Fig. 5, E and F), supporting the idea that the effect of LC ADAM17 deletion involved EGFR signals. In vitro, ADAM17 deficiency or blockade rendered LCs unable to protect keratinocytes from UVR-induced apoptosis in both murine and human systems (Fig. 5, G and H). These results together strongly supported the idea that LCs limit UVR effects via ADAM17 and stimulating keratinocyte EGFR.

The rapid LC-dependent increase in epidermal EGFR activation with UVR suggested that LC ADAM17 could be activated by UVR. To measure ADAM17 activity, we quantified the level of cell-surface tumor necrosis factor receptor 1 (TNFR1), a substrate for ADAM17 (31). Treatment with phorbol 12-myristate 13-acetate (PMA), a known ADAM17 activator (31), reduced murine LC TNFR1 in an ADAM17-dependent manner, as expected (Fig. 6A). Similar to PMA, UVR rapidly reduced TNFR1 on both murine and human LCs (Fig. 6, A and B). This effect was abrogated by *Adam17* deletion or ADAM17 blockade (Fig. 6, A and B). These results suggested that ADAM17 on LCs can be rapidly activated by UVR.

To examine whether the UVR-induced ADAM17 activation actually resulted in EGFR ligand cleavage and release, we collected conditioned supernatants from UVR-exposed LCs and assessed how well the supernatants induced EGFR phosphorylation in EGFR-overexpressing A431 indicator cells (fig. S8, A and B). In contrast to supernatants from murine or human LCs that were not exposed to UVR, supernatants from UVR-exposed LCs induced a robust increase in A431 cell EGFR phosphorylation, and *Adam17* deletion or ADAM17 blockade abolished this effect (Fig. 6, C and D). UVR has been shown to activate ADAM17 on keratinocytes (35), and UVR exposure also caused murine keratinocytes to release more EGFR ligands, although this effect was less pronounced than that seen in the LCs (fig. S8C). These data further established that UVR can trigger ADAM17 activation on LCs and showed that this activation can result in greater availability of active EGFR ligand. Together, our results show a central role for LCs and LC-derived ADAM17 in vivo and UVR-induced ADAM17 activation on

LCs ex vivo, suggesting that there is an LC-keratinocyte axis whereby UVR induces LC ADAM17 activation and consequent EGFR ligand cleavage, leading to increased keratinocyte EGFR activation, which limits UVR-induced keratinocyte apoptosis and skin injury.

The LC-keratinocyte axis is dysfunctional in photosensitive SLE models and human SLE

We asked whether photosensitivity in SLE models, at least in part, reflected dysfunction of this LC-keratinocyte axis. The MRL-*Fas*^{lpr} SLE model is a known photosensitive strain, developing more UVR-induced skin pathology than control Balb/c and/or MRL-MpJ mice (36, 37). UVR induces increased apoptotic keratinocyte accumulation in MRL-*Fas*^{lpr} mice (Fig. 7A) (36) along with skin plasma cell accumulation (fig. S9A). Consistent with the possibility of a dysfunctional LC-keratinocyte axis, MRL-*Fas*^{lpr} mice showed reduced UVR-induced EGFR phosphorylation (Fig. 7B).

LC numbers are comparable between MRL-*Fas*^{lpr} mice and Balb/c controls (38), and we asked about their ability to protect the skin. MRL-*Fas*^{lpr} LCs showed a trend toward reduced expression of epigen, the most abundantly expressed EGFR ligand, with UVR and reduced expression of epiregulin (fig. S9B), a ligand with relatively low expression (Fig. 4A). *Adam17* mRNA, on the other hand, was reduced in MRL-*Fas*^{lpr} mice by about 70% at homeostasis and after UVR exposure (Fig. 7C). Consistent with the reduced *Adam17* expression, MRL-*Fas*^{lpr} LCs showed no UVR-induced ADAM17 activation as indicated by TNFR1 changes or release of EGFR ligands (fig. S9, C and D). In vitro, MRL-*Fas*^{lpr} LCs did not limit UVR-induced keratinocyte apoptosis (Fig. 7D), whereas control LCs could limit UVR-induced apoptosis of MRL-*Fas*^{lpr} keratinocytes (Fig. 7D), suggesting that LC dysfunction was the critical defect




Fig. 5. LC-derived ADAM17 limits UVR-induced keratinocyte apoptosis and skin injury. (A to D) WT and LC-Ad17 mice were treated with UVR and analyzed at indicated time points. (A) Activated caspase-3⁺ keratinocytes ($n = 3$ to 5 mice). (B) Absolute (left) and normalized (right) monocyte numbers ($n = 4$ to 7 mice). (C) Epidermal thickness ($n = 3$ to 4 mice). (D) Epidermal permeability ($n = 3$ to 5 mice). Left: Representative images. Right: Quantification. (E and F) Vehicle or HB-EGF was applied on the ears before UVR exposure ($n = 3$ to 4 mice). (E) Activated caspase-3⁺ keratinocytes. (F) Absolute (left) and normalized (right) monocyte numbers. (G and H) Effect of LC *Adam17* deletion or ADAM17 blockade on keratinocyte survival in vitro. Murine keratinocytes with LCs from indicated mice (G) and human keratinocytes with control immunoglobulin G (IgG) or anti-ADAM17-treated LCs (H) were exposed to UVR and examined at 24 hours ($n = 3$ mice, $n = 4$ human donors). Data are from three (E to G), four (A), two (H), five (B), and one (C and D) independent experiments. Bars represent means (A, B, and D to H) or medians (C). Error bars depict SDs (A, B, and D to H) or interquartile ranges (C). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ using two-tailed unpaired Student's *t* test (A, B, and D to H) or nonparametric nondirectional Mann-Whitney *U* test after one-way ANOVA (C).

leading to increased UVR sensitivity in MRL-*Fas*^{lpr} mice. These data together suggested that MRL-*Fas*^{lpr} LCs, because of reduced ADAM17 and potentially because of reduced EGFR ligand expression, were unable to stimulate epidermal EGFR, thus contributing to photosensitivity.

We also examined the B6.Sle1^{ya} model of SLE. These mice carry the Sle1 lupus susceptibility locus derived from lupus-prone NZB2410 mice along with the Y chromosome autoimmune accelerator locus whose activity is attributable to Toll-like receptor 7 duplication (39). The mice develop lymphadenopathy by 3 months (fig. S10A), splenomegaly and autoantibody production by 4 months, and nephritis by 12 months (40). However, the photosensitivity of this model is unknown. Six-week-old B6.Sle1^{ya} mice did not show increased UVR-induced keratinocyte apoptosis (fig. S10B), but 8- to 12-month-old B6.Sle1^{ya} mice did (Fig. 7E). Upon multiday UVR treatment, 8- to 12-month-old B6.Sle1^{ya} mice developed skin lesions as early as 2 days, whereas B6 mice did not (fig. S10C). The skin findings were associated with the presence of plasma cells in the skin (fig. S10D). These results indicated that diseased B6.Sle1^{ya} mice are photosensitive.

The 8- to 12-month-old B6.Sle1^{ya} mice also showed reduced UVR-induced epidermal EGFR activation relative to controls (Fig. 7F). LC numbers were unchanged, and only the EGFR ligand amphiregulin was reduced (fig. S10, E and F), but B6.Sle1^{ya} LCs showed reduced *Adam17* mRNA expression (Fig. 7G). Together, these data suggested that photosensitivity in both SLE models may be attributable, at least in part, to a dysfunctional LC-keratinocyte axis whereby LCs are less able to produce activated EGFR ligands to stimulate keratinocyte EGFR.

We examined human SLE skin for signs of a dysfunctional LC-keratinocyte axis. Nonsun-exposed, nonlesional SLE skin showed decreased LC numbers relative to healthy control skin (Fig. 7H), suggesting an abnormality in LC function and a potential for reduced input of EGFR ligands. Epidermal EGFR phosphorylation was also reduced in SLE skin (Fig. 7I). These data support the idea that the LC-keratinocyte axis is dysfunctional in human SLE.




Fig. 6. UVR directly activates LC ADAM17 and EGFR ligand release. (A and B) Effect of UVR on ADAM17 activity in sorted murine (A) and human (B) LCs as measured by change in TNFR1 mean fluorescence intensity (MFI) 45 min after the indicated treatments. PMA is a positive control ($n = 5$ to 6 mice, $n = 4$ human donors). (C and D) Conditioned supernatants from murine (C) or human LCs (D) were added to A431 EGFR indicator cells, and phosphoEGFR was measured 10 min later by flow cytometry. Murine LC supernatants were from (A); human LC supernatants were from cells treated similarly to (B), except that the antibody was washed out before UVR (see the Supplementary Materials). Left: Representative histogram. Right: Quantification relative to cells treated with control WT LC supernatants (C) or control IgG-treated LC supernatants (D). Results are from six (A), two (B and D), and three (C) independent experiments. Bars represent means. Error bars depict SDs. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ using two-tailed unpaired Student's *t* test after one-way ANOVA.

Topical EGFR ligand reduces photosensitivity in an SLE model

We asked whether EGFR ligand supplementation could reduce photosensitivity in MRL-*Fas*^{pr} mice. Multiday UVR exposure has been shown to increase complement and immunoglobulin deposition in skin (36), and we observed that this regimen also led to ulcerations with a neutrophil-dominant infiltrate (Fig. 8, A to D, and fig. S11, A and B). Topical treatment with HB-EGF (Fig. 8A) reduced the severity of UVR-induced skin lesions (Fig. 8, B to D, and fig. S11, A and B) and monocyte accumulation (Fig. 8E). Topical HB-EGF also reduced germinal center B cells (fig. S11C) and plasma cells (fig. S11D) in skin-draining lymph nodes, suggesting that modulating skin EGFR signaling may affect systemic immunity. These findings suggest that compensating for a dysfunctional LC-keratinocyte axis by providing EGFR ligand can be used as an approach to treating photosensitivity.

DISCUSSION

LCs are best known as antigen-presenting cells, and our findings here establish LCs also as direct modulators of keratinocyte function and skin integrity whereby LCs limit sensitivity to UVR-induced keratinocyte apoptosis and skin injury. The mechanism requires LC expression of ADAM17, the metalloprotease that activates LC-expressed EGFR ligands to stimulate epidermal EGFR. LC abnormalities may contribute to dysfunction of the LC-keratinocyte axis in SLE, leading to photosensitivity, and EGFR ligand supplementation may be an approach to treating photosensitivity (fig. S12).

The LC-keratinocyte axis appears to be a stress survival mechanism. During homeostasis, keratinocyte ADAM17 plays a major role in maintaining skin integrity and barrier function (23), and our results indicating that LCs have only a modest role in maintaining epidermal EGFR phosphorylation during homeostasis are consistent with this. In contrast, LCs and LC ADAM17 had an important role in limiting skin injury with UVR, suggesting a scenario in which, in times of stress, keratinocytes require an extra source of EGFR ligands and LCs function as this source. That LC ADAM17 responded more robustly to UVR than keratinocyte ADAM17 further supported a role for LCs in providing a critical source of EGFR ligands in the setting of stress. This role in promoting survival during stress is similar to the role of DCs that we have delineated in inflamed lymph nodes and fibrotic skin (14, 15). Murine LCs are closely related to macrophages in ontogeny but have classical DC functions (10). Our findings suggest that LCs behave as DCs in maintaining epidermal integrity in times of stress.

Our model that LCs provide EGFR ligands to stimulate keratinocyte EGFR was supported by the UVR-induced increase in EGFR phosphorylation. In vitro, UVR-induced EGFR phosphorylation has been shown to involve both ligand-induced EGFR kinase activity (35, 41, 42) and reduction of protein receptor-type phosphatase κ activity (43). The inhibition of UVR-induced EGFR phosphorylation by an EGFR tyrosine kinase inhibitor in vivo supports the importance of EGFR kinase activity. Whether LCs also regulate phosphatase activity merits further study.

Our study adds to the recent developments showing rapid EGFR ligand production at barrier surfaces as a protective mechanism.




Fig. 7. Photosensitive SLE mouse models and human SLE skin show a dysfunctional LC-keratinocyte axis. WT and MRL-*Fas*^{pr} (*n* = 2 to 4 mice) (A to C) or B6.Sle1Yaa mice (*n* = 3 to 5 mice) (E to G) were treated and examined as indicated. (A and E) Activated caspase-3⁺ keratinocytes. (B and F) Epidermal EGFR phosphorylation 1 hour after UVR. Left: Representative Western blot. Right: pEGFR/tEGFR ratio. Uncropped Western blots are shown in fig. S13. (C and G) *LC Adam17* expression. (D) Effect of MRL-*Fas*^{pr} LCs on keratinocyte apoptosis. Balb/c or MRL-*Fas*^{pr} keratinocytes were exposed to UVR without or with indicated LCs (*n* = 3 mice). (H and I) LC numbers and epidermal EGFR phosphorylation in human SLE skin (*n* = 3 healthy controls, *n* = 10 to 13 SLE patients). Scale bars, 50 μ m. (H) Left: Representative images of anti-Langerin (purple) and DAPI (blue) staining. Right: LC numbers per millimeter of tissue. (I) Left: Representative images of anti-pEGFR (red), anti-tEGFR (green), and DAPI (blue) staining. Middle: Relative pEGFR/tEGFR fluorescence (fluor.) intensity normalized to healthy control skin. Right: Magnified inset from pEGFR and DAPI stain. Data are from three (A, B, D, E, and G to I) and two (C and F) independent experiments. Bars represent means. Error bars depict SDs. **P* < 0.05, ****P* < 0.001, *****P* < 0.0001 using two-tailed unpaired Student's *t* test. Student's *t* test was performed after one-way ANOVA for (A) to (D) and (F).

Regulatory T cells and group 2 innate lymphoid cells have recently been shown to be critical sources of the EGFR ligand amphiregulin in protecting lung and colonic epithelium, respectively, during inflammation (44, 45). In these models, amphiregulin expression was induced within days by alarmins from the injured tissues. In contrast, LCs were “immediate responders,” because LC-dependent epidermal phosphoEGFR up-regulation occurred by 1 hour after UVR in vivo, and UVR could act directly on LCs to activate LC ADAM17 ex vivo. Whether injured keratinocyte signals induce the up-regulation of LC epigen and amphiregulin at 24 hours and whether LCs are unique among immune cells in direct activation of ADAM17 are unknown. However, our study and that of others’ together suggest that there are distinct immediate versus early layers of regulation to protect barrier surfaces.

Hatakeyama *et al.* (46) recently suggested that LCs help to resolve UVR-induced skin inflammation at day 5 and later after UVR exposure by ingesting and clearing apoptotic keratinocytes. We show distinct findings, focusing on immediate events after UVR exposure. Furthermore, we detected essentially no activated caspase-3⁺ Langerin⁺ cells at 24 hours after exposure in WT mice and in LC-keratinocyte cocultures, suggesting that LC phagocytosis of apoptotic keratinocytes was minimal both in vivo and in vitro. Thus, although we do not rule out a role for LCs in clearing apoptotic keratinocytes at later time points, our study firmly establishes a role for LCs in limiting keratinocyte apoptosis early on.

Our study also suggested that LCs limit monocyte recruitment to the UVR-exposed skin and that accumulated monocytes contribute to increased epidermal permeability. UVR has long been noted to deplete LCs from the skin, and this depletion correlated with myeloid cell accumulation (47). Our results would suggest that the UVR-mediated depletion of LCs caused the myeloid cell accumulation and that stronger or chronic UVR exposure would further deplete LCs, leading to greater myeloid cell accumulation. EGFR activity has been shown to limit keratinocyte CCL2 expression (7), but the extent to which LCs alter chemokine expression by keratinocytes, fibroblasts, or endothelial cells needs to be examined




Fig. 8. Topical EGFR ligand reduces photosensitivity. (A) Experimental scheme for (B) to (E) ($n = 4$ mice). MRL-*Fas*^{pr} mouse ears and back skin were topically treated with HB-EGF for 2 days before and on the first day of UVR exposure and examined 24 hours after the final exposure. (B) Representative images of ears. The MRL-MpJ ear represents a non-SLE control. (C) Representative images of back skin; boxes outline lesional areas. Magnified images of back skin are shown in fig. S11. (D) Ear histopathology score. (E) Absolute monocyte numbers. (B to E) Data are from three independent experiments. Bars represent means. Error bars depict SDs. * $P < 0.05$, *** $P < 0.001$ using two-tailed unpaired Student's *t* test after one-way ANOVA.

more directly in future studies. Sontheimer *et al.* (48) recently showed that monocytes may be a major source of type I interferon a few days after UVR exposure, and it would be interesting to understand whether type I interferon increased epidermal permeability. Because UVR is also associated with immune suppression in healthy humans but increased autoimmunity in SLE patients (1, 47), it will be interesting to understand whether monocyte and monocyte-derived cells participate in differentially modulating immunity after UVR exposure in healthy and lupus erythematosus patients.

Our study is relevant for understanding photosensitivity in human disease in several ways. First, we showed that the LC-keratinocyte axis is dysfunctional in two SLE models, and the reduced EGFR phosphorylation in human SLE skin suggested that this axis may be dysfunctional and contribute to photosensitivity in human SLE. LC numbers were reduced in human SLE skin, and whether the reduced epidermal EGFR phosphorylation reflected the LC reduction, or other defects such as reduced LC ADAM17 or EGFR ligand expression, remains to be determined. Although LC-independent keratinocyte-intrinsic dysfunction may also lead to reduced epidermal EGFR phosphorylation and will need to be considered, the reduced LC numbers suggest failure of LC development or survival or perhaps increased migration to draining lymph nodes and suggest that LCs may be dysfunctional in human SLE. Second, our data showed that LCs protected at least UVA-mediated skin injury. Because sunlight is composed primarily of UVA (49), our data are relevant for better understanding the mechanisms that protect against the effects of sunlight exposure in lupus patients. Further understanding of LC function and regulation in SLE will be interesting, as will understanding whether there are similar defects in photosensitivity associated with other disorders (3).

There are a few limitations of this study. Although epidermal EGFR phosphorylation is reduced in human SLE skin, we do not yet know

whether human SLE LCs are less able to provide activated EGFR ligands or protect keratinocytes from UVR. We also do not yet understand how UVR activated ADAM17 or how LCs are dysregulated in the SLE models.

Our data suggest that topical EGFR stimulation could be a treatment to prevent the development of photosensitive cutaneous lesions in lupus erythematosus. The reduction in lymph node B cell responses with HB-EGF suggests that EGFR stimulation could also improve the systemic aspects of photosensitivity in SLE. Although the potential for carcinogenesis should be considered (50), topical EGF is being investigated for rashes associated with the use of EGFR inhibitors to treat lung cancer patients who are most likely immunocompromised (ClinicalTrials.gov; trials NCT03051880 and NCT03047863) (51). Furthermore, in mouse models of colitis-associated cancer, EGFR inhibited tumor development, likely by improving epidermal function and reducing inflammation (52). Our findings suggest that EGFR-

stimulating agents should be investigated for photosensitivity in lupus erythematosus and potentially other autoimmune and dermatologic conditions.

MATERIALS AND METHODS

Study design

Controlled experiments were designed using mouse models, *in vitro* systems, and human skin. Animals were randomly assigned to experimental groups. Sample sizes were determined on the basis of previously published experiments using similar tissues and assays (14, 15). No data were excluded, each experiment was performed with at least three biological replicates, and all data were reliably reproduced. Investigators were not blinded to group allocation during experiments and data acquisition. During data analysis, investigators were not blinded for flow cytometry, Western blot, epidermal permeability, and mRNA experiments but were blinded for histology/immunofluorescence and lesion measurements. Sample numbers and numbers of independent experiments are included in each figure legend. Each symbol in figures represents one mouse, human, or biological replicate. List of primary antibodies are in table S1 and secondary antibodies are in table S2. Primary data are included in table S3.

UVR treatments

In vivo, four FS40T12 sunlamps that emit UVA and UVB at a 40:60 ratio (20) were used as the UVR source. We determined 1000 J/m² UVR to be the minimal dose that caused visible dilation in the ears of C57BL/6J mice at 24 hours and used this dose for all experiments unless otherwise indicated. For multidose experiments with Langerin-DTA mice, mice were shaved 24 hours before the first UVR exposure. SLE model mice were shaved 24 hours before the first UVR exposure and then exposed to UVR (500 J/m²) for six consecutive days for

lesion development experiments. In vitro, mouse and human primary keratinocytes and LCs were exposed to UVR (500 J/m²) with the same UVR lamps as above.

Statistical analyses

For analyses of experiments with more than two groups, one-way ANOVA was initially used to examine differences among groups. For data that were normally distributed according to the Shapiro-Wilkes test, the ANOVA was followed by the two-tailed unpaired Student's *t* test to assess differences between two particular groups. For data that were not normally distributed, the nondirectional nonparametric Mann-Whitney *U* test was used to determine differences between two groups. For analyses of experiments with only two groups, we determined the distribution with the Shapiro-Wilkes test and then used the appropriate statistical test for comparison. The statistical test and measure of uncertainty used for each figure are included in the figure legend.

SUPPLEMENTARY MATERIALS

www.sciencetranslationalmedicine.org/cgi/content/full/10/454/eaap9527/DC1

Materials and Methods

Fig. S1. Additional features of LC-mediated protection from UVR-induced keratinocyte apoptosis and skin injury.

Fig. S2. The role of accumulated monocytes and monocyte-derived DCs in UVR-induced skin injury.

Fig. S3. Additional features of LC-mediated protection of keratinocytes in vitro.

Fig. S4. Mice treated with EGFR inhibitor resemble Langerin-DTA mice and timing of epidermal EGFR activation after UVR exposure.

Fig. S5. Effect of human LCs on human keratinocytes without UVR and further characterization of in vitro LC-keratinocyte EGFR signaling.

Fig. S6. Characterization of mouse and human ADAM17 expression, LC-Ad17 mice, and Langerin-Cre mice.

Fig. S7. Effects of inducible ADAM17 deletion in LCs.

Fig. S8. Validation of EGFR ligand release assay and characterization of keratinocyte EGFR ligand release.

Fig. S9. Photosensitive MRL-*Fas*^{lpr} mice have more skin plasma cells and reduced LC EGFR ligand expression, LC ADAM17 activity, and LC EGFR ligand release.

Fig. S10. B6.Sle1yaa mice exhibit photosensitivity and characterization of EGFR ligand expression by their LCs.

Fig. S11. EGFR ligand application reduces the severity of UVR-induced skin lesions and lymph node B cell responses in SLE model mice.

Fig. S12. Model of protective LC-keratinocyte axis and dysfunction of this axis in lupus photosensitivity.

Fig. S13. Uncropped Western blot images.

Table S1. List of primary antibodies.

Table S2. Secondary antibodies and other staining reagents.

Table S3. Primary data.

Reference (53)

REFERENCES AND NOTES

- M. K. Kuechle, K. B. Elkon, Shining light on lupus and UV. *Arthritis Res. Ther.* **9**, 101 (2007).
- B. F. Chong, V. P. Werth, in *Dubois' Lupus Erythematosus and Related Syndromes*, B. H. Hahn, Ed. (W.B. Saunders, ed. 8, 2013), pp. 319–332.
- T. P. Millard, J. L. M. Hawk, Photosensitivity disorders: Cause, effect, and management. *Am. J. Clin. Dermatol.* **3**, 239–246 (2002).
- T. D. Golan, K. B. Elkon, A. E. Gharavi, J. G. Krueger, Enhanced membrane binding of autoantibodies to cultured keratinocytes of systemic lupus erythematosus patients after ultraviolet B/ultraviolet A irradiation. *J. Clin. Invest.* **90**, 1067–1076 (1992).
- A. Kuhn, J. Wenzel, H. Weyd, Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: A critical review. *Clin. Rev. Allergy Immunol.* **47**, 1–15 (2014).
- E. Reefman, M. C. J. M. de Jong, H. Kuiper, M. F. Jonkman, P. C. Limburg, C. G. Kallenberg, M. Bijl, Is disturbed clearance of apoptotic keratinocytes responsible for UVB-induced inflammatory skin lesions in systemic lupus erythematosus? *Arthritis Res. Ther.* **8**, R156 (2006).
- B. M. Lichtenberger, P. A. Gerber, M. Holcman, B. A. Buhren, N. Amberg, V. Smolle, H. Schrumpf, E. Boelke, P. Ansari, C. Mackenzie, A. Wollenberg, A. Kislat, J. W. Fischer, K. Rock, J. Harder, J. M. Schröder, B. Homey, M. Sibilica, Epidermal EGFR controls cutaneous host defense and prevents inflammation. *Sci. Transl. Med.* **5**, 199ra111 (2013).
- D. Raj, D. E. Brash, D. Grossman, Keratinocyte apoptosis in epidermal development and disease. *J. Invest. Dermatol.* **126**, 243–257 (2006).
- S. W. Kashem, M. Haniffa, D. H. Kaplan, Antigen-presenting cells in the skin. *Annu. Rev. Immunol.* **35**, 469–499 (2017).
- T. Doebel, B. Voisin, K. Nagao, Langerhans cells—The macrophage in dendritic cell clothing. *Trends Immunol.* 817–828 (2017).
- R. D. Sontheimer, P. R. Bergstresser, Epidermal Langerhans cell involvement in cutaneous lupus erythematosus. *J. Invest. Dermatol.* **79**, 237–243 (1982).
- L. L. Teichmann, M. L. Ols, M. Kashgarian, B. Reizis, D. H. Kaplan, M. J. Shlomchik, Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. *Immunity* **33**, 967–978 (2010).
- J. K. King, R. L. Phillips, A. U. Eriksson, P. J. Kim, R. C. Halder, D. J. Lee, R. R. Singh, Langerhans cells maintain local tissue tolerance in a model of systemic autoimmune disease. *J. Immunol.* **195**, 464–476 (2015).
- J. J. Chia, T. Zhu, S. Chyou, D. C. Dasoveanu, C. Carballo, S. Tian, C. M. Magro, S. Rodeo, R. F. Spiera, N. H. Ruddle, T. E. McGraw, J. L. Browning, R. Lafyatis, J. K. Gordon, T. T. Lu, Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis. *J. Clin. Invest.* **126**, 4331–4345 (2016).
- V. Kumar, D. C. Dasoveanu, S. Chyou, T.-C. Tzeng, C. Roza, Y. Liang, W. Stohl, Y.-X. Fu, N. H. Ruddle, T. T. Lu, A dendritic-cell-stromal axis maintains immune responses in lymph nodes. *Immunity* **42**, 719–730 (2015).
- S. Ivanov, J. P. Scallan, K.-W. Kim, K. Werth, M. W. Johnson, B. T. Saunders, P. L. Wang, E. L. Kuan, A. C. Straub, M. Ouhachi, E. G. Weinstein, J. W. Williams, C. Briseño, M. Colonna, B. E. Isakson, E. L. Gautier, R. Förster, M. J. Davis, B. H. Zinselmeyer, G. J. Randolph, CCR7 and IRF4-dependent dendritic cells regulate lymphatic collecting vessel permeability. *J. Clin. Invest.* **126**, 1581–1591 (2016).
- J. L. Astarita, V. Cremasco, J. Fu, M. C. Darnell, J. R. Peck, J. M. Nieves-Bonilla, K. Song, Y. Kondo, M. C. Woodruff, A. Gogineni, L. Onder, B. Ludwig, R. M. Weimer, M. C. Carroll, D. J. Mooney, L. Xia, S. J. Turley, The CLEC-2-podoplanin axis controls the contractility of fibroblastic reticular cells and lymph node microarchitecture. *Nat. Immunol.* **16**, 75–84 (2015).
- S. E. Acton, A. J. Farrugia, J. L. Astarita, D. Mourão-Sá, R. P. Jenkins, E. Nye, S. Hooper, J. van Blijswijk, N. C. Rogers, K. J. Snelgrove, I. Rosewell, L. F. Moita, G. Stamp, S. J. Turley, E. Sahai, C. Reis e Sousa, Dendritic cells control fibroblastic reticular network tension and lymph node expansion. *Nature* **514**, 498–502 (2014).
- D. H. Kaplan, M. C. Jenison, S. Saeland, W. D. Shlomchik, M. J. Shlomchik, Epidermal Langerhans cell-deficient mice develop enhanced contact hypersensitivity. *Immunity* **23**, 611–620 (2005).
- L. Polla, R. Margolis, C. Goulston, J. A. Parrish, R. D. Granstein, Enhancement of the elicitation phase of the murine contact hypersensitivity response by prior exposure to local ultraviolet radiation. *J. Invest. Dermatol.* **86**, 13–17 (1986).
- T. B. El-Abaseri, S. Putta, L. A. Hansen, Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor. *Carcinogenesis* **27**, 225–231 (2006).
- A. Haratake, Y. Uchida, M. Schmuth, O. Tanno, R. Yasuda, J. H. Epstein, P. M. Elias, W. M. Holleran, UVB-induced alterations in permeability barrier function: Roles for epidermal hyperproliferation and thymocyte-mediated response. *J. Invest. Dermatol.* **108**, 769–775 (1997).
- C.-W. Franzke, C. Cobzaru, A. Triantafyllopoulou, S. Löffek, K. Horiuchi, D. W. Threadgill, T. Kurz, N. van Rooijen, L. Bruckner-Tuderman, C. P. Blobel, Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation. *J. Exp. Med.* **209**, 1105–1119 (2012).
- S. Tamoutounour, M. Guillemin, F. Montanana Sanchis, H. Liu, D. Terhorst, C. Malosse, E. Pollet, L. Ardouin, H. Luche, C. Sanchez, M. Dalod, B. Malissen, S. Henri, Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. *Immunity* **39**, 925–938 (2013).
- T. M. Hohl, A. Rivera, L. Lipuma, A. Gallegos, C. Shi, M. Mack, E. G. Pamer, Inflammatory monocytes facilitate adaptive CD4 T cell responses during respiratory fungal infection. *Cell Host Microbe* **6**, 470–481 (2009).
- J. L. Doerner, J. Wen, Y. Xia, K. B. Paz, D. Schairer, L. Wu, S. A. Chalmers, P. Izmirly, J. S. Michaelson, L. C. Burkly, A. J. Friedman, C. Putterman, TWEAK/Fn14 signaling involvement in the pathogenesis of cutaneous disease in the MRL/lpr model of spontaneous lupus. *J. Invest. Dermatol.* **135**, 1986–1995 (2015).
- M. S. Iordanov, R. J. Choi, O. P. Ryabinina, T.-H. Dinh, R. K. Bright, B. E. Magun, The UV (Ribotoxic) stress response of human keratinocytes involves the unexpected uncoupling of the ras-extracellular signal-regulated kinase signaling cascade from the activated epidermal growth factor receptor. *Mol. Cell. Biol.* **22**, 5380–5394 (2002).

28. F. Mascia, G. Lam, C. Keith, C. Garber, S. M. Steinberg, E. Kohn, S. H. Yuspa, Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. *Sci. Transl. Med.* **5**, 199ra110 (2013).
29. D. W. Fry, A. J. Bridges, W. A. Denny, A. Doherty, K. D. Greis, J. L. Hicks, K. E. Hook, P. R. Keller, W. R. Leopold, J. A. Loo, D. J. McNamara, J. M. Nelson, V. Sherwood, J. B. Smail, S. Trumpp-Kallmeyer, E. M. Dobrusin, Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 12022–12027 (1998).
30. T. Ronan, J. L. Macdonald-Obermann, L. Huelsmann, N. J. Bessman, K. M. Naegle, L. J. Pike, Different epidermal growth factor receptor (EGFR) agonists produce unique signatures for the recruitment of downstream signaling proteins. *J. Biol. Chem.* **291**, 5528–5540 (2016).
31. J. Scheller, A. Chalaris, C. Garbers, S. Rose-John, ADAM17: A molecular switch to control inflammation and tissue regeneration. *Trends Immunol.* **32**, 380–387 (2011).
32. K. Horiuchi, T. Kimura, T. Miyamoto, H. Takaishi, Y. Okada, Y. Toyama, C. P. Blobel, Cutting edge: TNF- α -converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. *J. Immunol.* **179**, 2686–2689 (2007).
33. D. H. Kaplan, M. O. Li, M. C. Jenison, W. D. Shlomchik, R. A. Flavell, M. J. Shlomchik, Autocrine/paracrine TGF β 1 is required for the development of epidermal Langerhans cells. *J. Exp. Med.* **204**, 2545–2552 (2007).
34. A. Bobr, B. Igyarto, K. M. Haley, M. O. Li, R. A. Flavell, D. H. Kaplan, Autocrine/paracrine TGF- β 1 inhibits Langerhans cell migration. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 10492–10497 (2012).
35. B. Singh, M. Schneider, P. Knyazev, A. Ullrich, UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines. *Int. J. Cancer* **124**, 531–539 (2009).
36. J. Menke, M.-Y. Hsu, K. T. Byrne, J. A. Lucas, W. A. Rabacal, B. P. Croker, X.-H. Zong, E. R. Stanley, V. R. Kelley, Sunlight triggers cutaneous lupus through a (CSF-1)-dependent mechanism in MRL-*Fas*^{pr} mice. *J. Immunol.* **181**, 7367–7379 (2008).
37. Y. Horiguchi, F. Furukawa, G. Ohshio, T. Horio, S. Imamura, Effects of ultraviolet light irradiation on the skin of MRL/l mice. *Arch. Dermatol. Res.* **279**, 478–483 (1987).
38. A. U. Eriksson, R. R. Singh, Cutting edge: Migration of Langerhans dendritic cells is impaired in autoimmune dermatitis. *J. Immunol.* **181**, 7468–7472 (2008).
39. P. Pisitkun, J. A. Deane, M. J. Difilippantonio, T. Tarasenko, A. B. Satterthwaite, S. Bolland, Autoreactive B cell responses to RNA-related antigens due to *TLR7* gene duplication. *Science* **312**, 1669–1672 (2006).
40. L. Morel, B. P. Croker, K. R. Blenman, C. Mohan, G. Huang, G. Gilkeson, E. K. Wakeland, Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 6670–6675 (2000).
41. R. P. Huang, J. X. Wu, Y. Fan, E. D. Adamson, UV activates growth factor receptors via reactive oxygen intermediates. *J. Cell Biol.* **133**, 211–220 (1996).
42. C. Sachsenmaier, A. Radler-Pohl, R. Zinck, A. Nordheim, P. Herrlich, H. J. Rahmsdorf, Involvement of growth factor receptors in the mammalian UVC response. *Cell* **78**, 963–972 (1994).
43. Y. Xu, Y. Shao, J. J. Voorhees, G. J. Fisher, Oxidative inhibition of receptor-type protein-tyrosine phosphatase κ by ultraviolet irradiation activates epidermal growth factor receptor in human keratinocytes. *J. Biol. Chem.* **281**, 27389–27397 (2006).
44. L. A. Monticelli, L. C. Osborne, M. Noti, S. V. Tran, D. M. W. Zaiss, D. Artis, IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. *Proc. Natl. Acad. Sci. U.S.A.* **112**, 10762–10767 (2015).
45. N. Arpaia, J. A. Green, B. Molledo, A. Arvey, S. Hemmers, S. Yuan, P. M. Treuting, A. Y. Rudensky, A distinct function of regulatory T cells in tissue protection. *Cell* **162**, 1078–1089 (2015).
46. M. Hatakeyama, A. Fukunaga, K. Washio, K. Taguchi, Y. Oda, K. Ogura, C. Nishigori, Anti-inflammatory role of Langerhans cells and apoptotic keratinocytes in ultraviolet-B-induced cutaneous inflammation. *J. Immunol.* 2937–2947 (2017).
47. K. D. Cooper, L. Oberhelman, T. A. Hamilton, O. Baadsgaard, M. Terhune, G. LeVee, T. Anderson, H. Koren, UV exposure reduces immunization rates and promotes tolerance to epicutaneous antigens in humans: Relationship to dose, CD1a-DR+ epidermal macrophage induction, and Langerhans cell depletion. *Proc. Natl. Acad. Sci. U.S.A.* **89**, 8497–8501 (1992).
48. C. Sontheimer, D. Liggitt, K. B. Elkon, Ultraviolet B irradiation causes stimulator of interferon genes-dependent production of protective type I interferon in mouse skin by recruited inflammatory monocytes. *Arthritis Rheumatol.* **69**, 826–836 (2017).
49. N. Kollias, E. Ruvolo Jr., R. M. Sayre, The value of the ratio of UVA to UVB in sunlight. *Photochem. Photobiol.* **87**, 1474–1475 (2011).
50. P. Uribe, S. Gonzalez, Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: Molecular bases for EGFR-targeted therapy. *Pathol. Res. Pract.* **207**, 337–342 (2011).
51. J. U. Shin, J. H. Park, B.-C. Cho, J. H. Lee, Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor. *Dermatology* **225**, 135–140 (2012).
52. P. E. Dubé, F. Yan, S. Punit, N. Girish, S. J. McElroy, M. K. Washington, D. B. Polk, Epidermal growth factor receptor inhibits colitis-associated cancer in mice. *J. Clin. Invest.* **122**, 2780–2792 (2012).
53. P. M. Izmirly, M. Shvartsbeyn, S. Meehan, A. Franks, A. Braun, E. Ginzler, S. X. Xu, H. Yee, T. Rivera, C. Esmon, L. Barisoni, J. T. Merrill, J. P. Buyon, R. M. Clancy, Dysregulation of the microvasculature in nonlesional non-sun-exposed skin of patients with lupus nephritis. *J. Rheumatol.* **39**, 510–515 (2012).

Acknowledgments: We thank I. Rogatsky's and A. Pernis's laboratories for helpful discussions and J. Szymonifka for help with the statistical analysis. **Funding:** This work was supported by NIH MSTP T32GM007739 to the Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program (to W.D.S.), NIH T32AR071302-01 to the Hospital for Special Surgery Research Institute Rheumatology Training Program (to W.D.S.), and NIH R01AI079178, Alliance for Lupus Research Target Identification grant, Lupus Research Institute Novel Research Grant, St. Giles Foundation, and an O'Neill Foundation grant from the Barbara Volcker Center for Women and Rheumatic Diseases (all to T.T.L.). The research was supported by the NIH Office of the Director grant S10OD019986 to Hospital for Special Surgery. The content of this work is solely the responsibility of the authors and does not necessarily represent official NIH views. **Author contributions:** W.D.S., S.C., A.R., S.S., and D.C.D. designed, performed, and interpreted experiments. T.P. and C.M.M. interpreted experiments. D.H.K., J.E.S., X.Q., E.G.P., B.J.M., J.W.Y., and C.P.B. provided reagents. P.M.I. and R.M.C. provided patient skin samples and slides. S.S., B.J.M., and J.W.Y. provided and processed fresh human skin samples. R.D.G., M.A.L., D.H.K., J.E.S., J.W.Y., R.M.C., and C.P.B. provided critical input during manuscript development and writing. T.T.L. designed, supervised, and interpreted experiments. W.D.S. and T.T.L. wrote the paper. **Competing interests:** The authors declare that they have no competing financial interests. **Data and materials availability:** No data sets were generated. All relevant data supporting the findings of this study are available within the paper and its Supplementary Materials.

Submitted 20 September 2017

Accepted 13 July 2018

Published 15 August 2018

10.1126/scitranslmed.aap9527

Citation: W. D. Shipman, S. Chyou, A. Ramanathan, P. M. Izmirly, S. Sharma, T. Pannellini, D. C. Dasoveanu, X. Qing, C. M. Magro, R. D. Granstein, M. A. Lowes, E. G. Pamer, D. H. Kaplan, J. E. Salmon, B. J. Mehara, J. W. Young, R. M. Clancy, C. P. Blobel, T. T. Lu, A protective Langerhans cell-keratinocyte axis that is dysfunctional in photosensitivity. *Sci. Transl. Med.* **10**, eaap9527 (2018).

A protective Langerhans cell–keratinocyte axis that is dysfunctional in photosensitivity

William D. Shipman, Susan Chyou, Anusha Ramanathan, Peter M. Izmirly, Sneha Sharma, Tania Pannellini, Dragos C. Dasoveanu, Xiaoping Qing, Cynthia M. Magro, Richard D. Granstein, Michelle A. Lowes, Eric G. Pamer, Daniel H. Kaplan, Jane E. Salmon, Babak J. Mehrara, James W. Young, Robert M. Clancy, Carl P. Blobel and Theresa T. Lu

Sci Transl Med 10, eaap9527.
DOI: 10.1126/scitranslmed.aap9527

Abrogating keratinocyte apoptosis in lupus

Lupus patients can experience photosensitivity as manifested by joint pain, fatigue, and skin rashes. To better understand the mechanisms behind this photosensitivity, Shipman *et al.* examined patient skin samples and mouse models of lupus. They saw that, in healthy mice and human skin exposed to ultraviolet radiation, Langerhans cells protected keratinocytes from apoptosis through a mechanism involving the metalloproteinase ADAM17 and EGFR ligands. In the lupus mice and patient samples, the Langerhans cells were unable to do this. Stimulating EGFR in the skin may bring relief to photosensitive lupus patients.

ARTICLE TOOLS

<http://stm.sciencemag.org/content/10/454/eaap9527>

SUPPLEMENTARY MATERIALS

<http://stm.sciencemag.org/content/suppl/2018/08/13/10.454.eaap9527.DC1>

RELATED CONTENT

<http://stm.sciencemag.org/content/scitransmed/10/434/eaan2306.full>
<http://stm.sciencemag.org/content/scitransmed/10/423/eaam8458.full>
<http://stm.sciencemag.org/content/scitransmed/10/450/eaam7710.full>
<http://stm.sciencemag.org/content/scitransmed/10/440/eaao4650.full>
<http://stm.sciencemag.org/content/scitransmed/11/480/eaau0683.full>
<http://stm.sciencemag.org/content/scitransmed/11/508/eaav5908.full>
<http://stm.sciencemag.org/content/scitransmed/11/511/eaav7561.full>
<http://stm.sciencemag.org/content/scitransmed/11/522/eaax1159.full>

REFERENCES

This article cites 50 articles, 19 of which you can access for free
<http://stm.sciencemag.org/content/10/454/eaap9527#BIBL>

PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)

Science Translational Medicine (ISSN 1946-6242) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science Translational Medicine* is a registered trademark of AAAS.

Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works